Yahoo Finance • last year

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to t... Full story

Yahoo Finance • last year

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic dise... Full story

Yahoo Finance • last year

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as... Full story

Yahoo Finance • last year

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as... Full story

Yahoo Finance • last year

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as... Full story

Yahoo Finance • last year

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

ATLANTA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as... Full story

Yahoo Finance • 2 years ago

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, includin... Full story

Yahoo Finance • 2 years ago

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic... Full story

Yahoo Finance • 2 years ago

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

-Virios’ IMC-1 Phase 3 Proposed Program is Considered Acceptable based on Initial FDA Feedback Pending Review of the Final Chronic Toxicology Program Results- -Final Toxicology Results to be Submitted to FDA in May 2023- -Company will Pr... Full story

Yahoo Finance • 2 years ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

ATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, includ... Full story

Yahoo Finance • 2 years ago

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

ATLANTA, March 07, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia... Full story

Yahoo Finance • 2 years ago

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

ATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including f... Full story

Yahoo Finance • 2 years ago

Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program

ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) --  Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including... Full story